Benchmarking Quality in the Healthcare Sector: Staffing, Resources, and Investment

STUDY OVERVIEW

Best Practices, LLC conducted this study to provide current benchmarks on quality staffing and investment levels within biopharma and medical device companies. In particular, the study presents ratios of quality staff to total FTEs for biopharma and medical device companies; quality staffing by areas such as GLP and GMP; and span of control metrics across five supervisory levels. The research also has investment benchmarks such as ratios for quality spend to company revenue and quality spend per quality FTE.

Quality leaders can use this study to assess their quality staffing and investment levels.

KEY TOPICS

• Staffing and Resource Benchmarks
• Investment and Resource Benchmarks

SAMPLE KEY METRICS

• Average quality staffing ratio of quality FTEs to total FTEs for biopharma and medical device participants
• What are your total quality FTEs (internal and outsourced)
• What are your total internal quality FTEs
• What is your quality staffing allocation by these quality areas (GLP, GMP, etc.)
• Number of direct reports for these five supervisory levels (vice president, director, etc.)
• How has the total number of quality FTEs changed in the past 3 years and what do you expect for the next 3 years
• Average quality spend ratio of quality spend to company revenue
• What is the average revenue supported by a quality FTE

SAMPLE KEY FINDINGS

• Quality staffing resources density at benchmark companies is 9.6% while 7.2% for Biopharma
• Span of control ranges vary by 50% -- reflecting cost-risk tradeoffs and efficiency opportunities

METHODOLOGY

The research employed a data gathering approach that reaps quantitative & qualitative data from
a diverse group of 22 companies. This study includes segmented data for biopharma and medical device companies.

Industries Profiled:
Medical Device; Pharmaceutical; Diagnostic; Manufacturing; Consulting; Biotech; Biopharmaceutical; Health Care; Clinical Research; Laboratories


Companies Profiled:
Boston Scientific; idera pharmaceuticals; Astellas; seracare; GlaxoSmithKline ; GN Hearing; 3M Company; Neopharm; Amgen; NewLink Genetics; Abbvie; Takeda Pharmaceuticals; Daiichi Sankyo; DePuy Synthes; Baxter Healthcare; Novartis; Tesaro; Biogen; Sanofi; Abbott; Medtronic; Beckman Coulter

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.